At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients With Tumors With CDK4 or CDK6 Amplification
In Brief
A Phase 2 clinical trial evaluating Biopsy Procedure, Biospecimen Collection, and 3 other interventions for Advanced Lymphoma and 3 related conditions. Active but no longer recruiting, targeting 43 participants across 1 site.
Detailed Summary
This phase II MATCH treatment trial tests how well palbociclib (PD-0332991) works in treating patients with cancer that has certain genetic changes. Palbociclib (PD-0332991) is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the CDK4 or CDK6 gene. It works by blocking the action of mutated CDK4 or CDK6 that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.
Study Details
Timeline
Interventions
Undergo biopsy
Undergo blood sample collection
Undergo CT scan
Undergo MRI
Given PO